DMII (Drugs Made In America Acquisition II) Current Accrued Expense: $0.17 Mil (As of Mar. 2026)


DMII Drugs Made In America Acquisition II Corp DMII
15 GF Score
Price $10.10
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition II Current Accrued Expense?

Drugs Made In America Acquisition II DMII 15 Current Accrued Expense is $0.17 Mil as of Mar. 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Drugs Made In America Acquisition II's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.17 Mil.

Drugs Made In America Acquisition II's quarterly Current Accrued Expense increased from Sep. 2025 ($0.12 Mil) to Dec. 2025 ($0.20 Mil) but then declined from Dec. 2025 ($0.20 Mil) to Mar. 2026 ($0.17 Mil).

Drugs Made In America Acquisition II's annual Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.01 Mil) and increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.20 Mil).

Drugs Made In America Acquisition II Current Accrued Expense Related Terms

Drugs Made In America Acquisition II Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition II's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition II Current Accrued Expense Chart

Drugs Made In America Acquisition II Annual Data
Trend Dec24 Dec25
Current Accrued Expense
0.01 0.20

Drugs Made In America Acquisition II Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial 0.03 0.03 0.12 0.20 0.17
DMII
15GF Score
Drugs Made In America Acquisition II Corp DMII
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition II Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.17 Mil mean?
Drugs Made In America Acquisition II (DMII) has a Current Accrued Expense of $0.17 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Drugs Made In America Acquisition II and its competitors.
Is Drugs Made In America Acquisition II's Current Accrued Expense too high?
Drugs Made In America Acquisition II's current Current Accrued Expense is $0.17 Mil. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's Current Accrued Expense compare to BCSS and EVAC?
Drugs Made In America Acquisition II's Current Accrued Expense of $0.17 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Diversified Financial Services company?
A good Current Accrued Expense depends on the Diversified Financial Services industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Drugs Made In America Acquisition II and its competitors. Drugs Made In America Acquisition II's current Current Accrued Expense is $0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current Current Accrued Expense of $0.17 Mil. The current Current Accrued Expense is $0.17 Mil. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current Current Accrued Expense is $0.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition II Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition II Corp is a blank check Company.
15GF Score

Get the complete analysis for DMII

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.10
Price